Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

Published:2019-03 Issue:3 Volume:19 Page:162-166
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Assunção Paola Morelato,Lana Tamires Prates,Delamain Márcia Torresan,Duarte Gislaine Oliveira,Zulli Roberto,Lorand-Metze Irene,de Souza Carmino Antonio^ORCID,de Paula Erich Vinicius^ORCID,Barbosa Pagnano Katia Borgia^ORCID

Funder

CAPES

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. Portaria SAS no 1219, de 14 de novembro de 2013, Protocolo e Diretrizes Terapêuticas para o tratamento da Leucemia Mieloide Crônica;Diário Of da União,2013

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

3. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure;Kantarjian;Cancer,2007

4. Chronic myeloid leukemia: mechanisms of resistance and treatment;Elias;Hematol Oncol Clin North Am,2011

5. Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia;Moslehi;J Clin Oncol,2015

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08

2. Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary;Pathology and Oncology Research;2024-02-20

3. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities;International Journal of Hematology;2022-09-05

4. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel;Blood Advances;2021-11-24

5. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study;The Oncologist;2021-09-12